These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 15000421)

  • 1. Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance.
    Zhang L; Beal SL; Sheiner LB
    J Pharmacokinet Pharmacodyn; 2003 Dec; 30(6):387-404. PubMed ID: 15000421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous vs. sequential analysis for population PK/PD data II: robustness of methods.
    Zhang L; Beal SL; Sheinerz LB
    J Pharmacokinet Pharmacodyn; 2003 Dec; 30(6):405-16. PubMed ID: 15000422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies.
    Bustad A; Terziivanov D; Leary R; Port R; Schumitzky A; Jelliffe R
    Clin Pharmacokinet; 2006; 45(4):365-83. PubMed ID: 16584284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Designs for population pharmacodynamics: value of pharmacokinetic data and population analysis.
    Hashimoto Y; Sheiner LB
    J Pharmacokinet Biopharm; 1991 Jun; 19(3):333-53. PubMed ID: 1875286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simultaneous versus sequential pharmacokinetic-pharmacodynamic population analysis using an iterative two-stage Bayesian technique.
    Proost JH; Schiere S; Eleveld DJ; Wierda JM
    Biopharm Drug Dispos; 2007 Nov; 28(8):455-73. PubMed ID: 17847121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of the SAEM algorithm in MONOLIX software for estimation of population pharmacokinetic-pharmacodynamic-viral dynamics parameters of maraviroc in asymptomatic HIV subjects.
    Chan PL; Jacqmin P; Lavielle M; McFadyen L; Weatherley B
    J Pharmacokinet Pharmacodyn; 2011 Feb; 38(1):41-61. PubMed ID: 21088872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of IPPSE, an alternative method for sequential population PKPD analysis.
    Lacroix BD; Friberg LE; Karlsson MO
    J Pharmacokinet Pharmacodyn; 2012 Apr; 39(2):177-93. PubMed ID: 22270323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneous population optimal design for pharmacokinetic-pharmacodynamic experiments.
    Hooker A; Vicini P
    AAPS J; 2005 Nov; 7(4):E759-85. PubMed ID: 16594631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Approaches to handling pharmacodynamic baseline responses.
    Dansirikul C; Silber HE; Karlsson MO
    J Pharmacokinet Pharmacodyn; 2008 Jun; 35(3):269-83. PubMed ID: 18446428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Building population pharmacokinetic--pharmacodynamic models. I. Models for covariate effects.
    Mandema JW; Verotta D; Sheiner LB
    J Pharmacokinet Biopharm; 1992 Oct; 20(5):511-28. PubMed ID: 1287200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacometrics: modelling and simulation tools to improve decision making in clinical drug development.
    Gieschke R; Steimer JL
    Eur J Drug Metab Pharmacokinet; 2000; 25(1):49-58. PubMed ID: 11032091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modelling response time profiles in the absence of drug concentrations: definition and performance evaluation of the K-PD model.
    Jacqmin P; Snoeck E; van Schaick EA; Gieschke R; Pillai P; Steimer JL; Girard P
    J Pharmacokinet Pharmacodyn; 2007 Feb; 34(1):57-85. PubMed ID: 17051439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An evaluation of population D-optimal designs via pharmacokinetic simulations.
    Hooker AC; Foracchia M; Dodds MG; Vicini P
    Ann Biomed Eng; 2003 Jan; 31(1):98-111. PubMed ID: 12572660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling.
    Meibohm B; Derendorf H
    Int J Clin Pharmacol Ther; 1997 Oct; 35(10):401-13. PubMed ID: 9352388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic-pharmacodynamic model for educational simulations.
    van Meurs WL; Nikkelen E; Good ML
    IEEE Trans Biomed Eng; 1998 May; 45(5):582-90. PubMed ID: 9581056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic-pharmacodynamic (PK-PD) modelling in non-steady-state studies and arterio-venous drug concentration differences.
    Gumbleton M; Oie S; Verotta D
    Br J Clin Pharmacol; 1994 Nov; 38(5):389-400. PubMed ID: 7893578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check.
    Yano Y; Beal SL; Sheiner LB
    J Pharmacokinet Pharmacodyn; 2001 Apr; 28(2):171-92. PubMed ID: 11381569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sample size computations for PK/PD population models.
    Kang D; Schwartz JB; Verotta D
    J Pharmacokinet Pharmacodyn; 2005 Dec; 32(5-6):685-701. PubMed ID: 16284914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Performance of different population pharmacokinetic algorithms.
    Colucci P; Grenier J; Yue CS; Turgeon J; Ducharme MP
    Ther Drug Monit; 2011 Oct; 33(5):583-91. PubMed ID: 21912327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simultaneous optimal experimental design on dose and sample times.
    Nyberg J; Karlsson MO; Hooker AC
    J Pharmacokinet Pharmacodyn; 2009 Apr; 36(2):125-45. PubMed ID: 19319484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.